Baxter(US:BAX) Newsfile·2025-11-12 00:33Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. regarding a federal securities class action lawsuit, with a lead plaintiff deadline set for December 15, 2025 [2][5]. Group 1: Legal Action and Deadlines - Investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. - The deadline for seeking the role of lead plaintiff in the class action lawsuit is December 15, 2025 [2]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by making false or misleading statements regarding the Novum LVP, which suffered systemic defects leading to serious patient risks [5]. - Specific allegations include that Baxter was aware of multiple device malfunctions and injuries but failed to adequately address these issues, resulting in a heightened risk of product recalls and sales pauses [5]. Group 3: Impact on Stock Performance - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause on shipments and installations of the Novum LVP, causing the stock to drop by 22.4%, closing at $21.76 [6].